Trial · NCT06992674
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Moderate/Severe vestibular symptom days | from baseline to weeks 12-16 | Change in number of Moderate/Severe vestibular symptom days as defined by Barany Society1 for participants measured daily from the observational phase compared to weeks 12-16. |
| Secondary | Moderate/Severe vestibular symptom days | every 4 weeks during the 12-week treatment period compared to baseline | Change in number of Moderate/Severe vestibular symptom days as defined by Barany Society1 every 4 weeks during the 12-week treatment period compared to baseline |
| Secondary | the number of vestibular symptom attacks | every 4 weeks compared to baseline over the 12-week treatment period | Change in the number of vestibular symptom attacks every 4 weeks compared to baseline over the 12-week treatment period. (Since VM attacks may recur multiple times within a day, each lasting a short duration, we need to further clearly define what constitutes "one attack.") |
| Secondary | MMD | every 4 weeks compared to baseline over the 12-week treatment period | Change in the number of monthly migraine days (MMD) every 4 weeks compared to baseline over the 12-week treatment period |
| Secondary | MIDAS | from baseline to week 16 | Change in Migraine Disability Assessment (MIDAS) score from baseline to week 16 |
| Secondary | percentage reduction in moderate/severe vestibular symptom days | from baseline to weeks 12-16 | Change in response rate (100%,75%,50%,25%,0%) by percentage reduction in moderate/severe vestibular symptom days from baseline to weeks 12-16 |
| Secondary | DHI | from baseline to week 16 | Change in dizziness handicap inventory (DHI) score from baseline to week 16 |
| Secondary | VADL | from baseline to week 16 | Change in Vestibular Activities of Daily Living Scale (VADL) score from baseline to week 16 |
| Secondary | PHQ-9 | from baseline to week 16 | Change in Patient Health Questionnaire-9 (PHQ-9) score from baseline to week 16 |
| Secondary | GAD-7 | from baseline to week 16 | Change in General Anxiety Disorder-7 (GAD-7) score from baseline to week 16 |
| Secondary | PGIC | from baseline to week 16 | Change in Patient Global Impression of Change（PGIC scale）from baseline to week 16 |
| Secondary | MSQ | from baseline to week 16 | Change in Migraine-Specific Quality of Life (MSQ) score from baseline to week 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06992674/registered